Dynamic immune cell profiling identified natural killer cell shift as the key event in early allograft dysfunction after liver transplantation
Cell Proliferation · 2024-04 · 57 (4)
DOI: 10.1111/cpr.13568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, online erschienen am 31.10.2023. Verfasst von Di Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Liver Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Program, National Natural Science Foundation of China, Key R&D Program of Zhejiang, National Key Research and Development Program of China.
Abstract (Originalsprache)
Early allograft dysfunction (EAD) is a life‐threatening and fast‐developing complication after liver transplantation. The underlying mechanism needs to be better understood, and there has yet to be an efficient therapeutic target. This study retrospectively reviewed 109 patients undergoing liver transplantation, with dynamic profiling of CD3/4/8/16/19/45/56 on the peripheral immune cells (before transplant and 2–4 days after). Altogether, 35 out of the 109 patients developed EAD after liver transplantation. We observed a significant decrease in the natural killer cell proportion (NK cell shift, p = 0.008). The NK cell shift was linearly correlated with cold ischemic time ( p = 0.016) and was potentially related to the recipients' outcomes. In mouse models, ischemic/reperfusion (I/R) treatments induced the recruitment of NK cells from peripheral blood into liver tissues. NK cell depletion blocked a series of immune cascades (including CD8+ CD127+ T cells) and inhibited hepatocyte injury effectively in I/R and liver transplantation models. We further found that I/R treatment increased hepatic expression of the ligands for natural killer group 2 member D (NKG2D), a primary activating cell surface receptor in NK cells. Blockade of NKG2D showed a similar protective effect against I/R injury, indicating its role in NK cell activation and the subsequent immunological injury. Our findings built a bridge for the translation from innate immune response to EAD at the bedside. Peripheral NK cell shift is associated with the incidence of EAD after liver transplantation. NKG2D‐mediated NK cell activation is a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Zhejiang University School of Medicine, Hangzhou, China.
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, China.
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, China.
ORCID-Profile: Shusen Zheng, Xiao Xu
Förderung
- Key Program, National Natural Science Foundation of China
- Key R&D Program of Zhejiang
- National Key Research and Development Program of China
- Young Program of National Natural Science Funds of China
Zitieren
APA
Lu, D., Yang, X., Pan, L., Lian, Z., Tan, W., Zhuo, J., Yang, M., Lin, Z., Wei, Q., Chen, J., Zheng, S., & Xu, X. (2024). Dynamic immune cell profiling identified natural killer cell shift as the key event in early allograft dysfunction after liver transplantation. Cell Proliferation, 57(4). https://doi.org/10.1111/cpr.13568
Vancouver
Lu D, Yang X, Pan L, Lian Z, Tan W, Zhuo J, et al. Dynamic immune cell profiling identified natural killer cell shift as the key event in early allograft dysfunction after liver transplantation. Cell Proliferation. 2024;57(4). doi:10.1111/cpr.13568
BibTeX
@article{Lu2024,
author = {Lu, Di and Yang, Xinyu and Pan, Linhui and Lian, Zhengxing and Tan, Winyen and Zhuo, Jianyong and Yang, Modan and Lin, Zuyuan and Wei, Qiang and Chen, Jun and Zheng, Shusen and Xu, Xiao},
title = {Dynamic immune cell profiling identified natural killer cell shift as the key event in early allograft dysfunction after liver transplantation},
journal = {Cell Proliferation},
year = {2024},
volume = {57},
number = {4},
doi = {10.1111/cpr.13568}
}
EUVIMED